Literature DB >> 17504233

Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages.

Bruce D Uhal1, Jong Kyong Kim, Xiaopeng Li, Maria Molina-Molina.   

Abstract

Angiotensin II (ANGII) has been identified as a proapoptotic and profibrotic factor in experimental lung fibrosis models, and patients with the ID/DD polymorphism of ANG converting enzyme (ACE), which confers higher levels of ACE, are predisposed to lung fibrosis (Hum. Pathol. 32:521-528, 2001). Previous work from this laboratory has shown that human lung myofibroblasts isolated from patients with Idiopathic Pulmonary Fibrosis (IPF) synthesize the ANGII precursor angiotensinogen (AGT) constitutively. In attempts to understand the mechanisms and consequences of constitutive AGT synthesis by myofibroblasts, we studied myofibroblast-rich primary cultures of lung fibroblasts from patients with IPF (HIPF isolates), primary fibroblasts from normal human lung (NLFs), the IMR90 and WI38 human lung fibroblasts cell lines, and paraffin sections of lung biopsies from patients with IPF. Compared to the normal NLF isolates, HIPF primary fibroblast isolates constitutively synthesized more AGT and TGF-beta1 mRNA, and released more AGT protein, ANGII and active TGF-beta1 protein into serum-free conditioned media (both p<0.01). Incubation of HIPF fibrotic isolates with the ANGII receptor antagonist saralasin reduced both TGF-beta1 mRNA and active protein, suggesting that the constitutive expression of AGT drives the higher expression of TGF-beta1 by the HIPF cells. Consistent with this premise, treatment of either the primary NLFs or the WI38 cell line with 10(-7) M ANGII increased both TGF-beta1 mRNA and soluble active TGF-beta1 protein. Moreover, induction of the myofibroblast transition in the IMR90 cell line with 2 ng/ml TGF-beta1 increased steady state AGT mRNA levels by realtime PCR (8-fold, p<0.01) and induced expression of an AGT promoter-luciferase reporter construct by over 10-fold (p<0.001). Antisense oligonucleotides against TGF-beta1 mRNA or TGF-beta neutralizing antibodies, when applied to the fibrotic HIPF cells in serum-free medium, significantly reduced AGT expression. In lung sections from IPF patient biopsies, immunoreactive AGT/ANGI proteins were detected in myofibroblasts, epithelial cells and presumptive alveolar macrophages. Together, these data support the existence of an angiotensin/TGF-beta1 "autocrine loop" in human lung myofibroblasts and also suggest ANG peptide expression by epithelia and macrophages in the IPF lung. These findings may explain the ability of ACE inhibitors and ANG receptor antagonists to block experimental lung fibrosis in animals, and support the need for evaluation of these agents for potential treatment of human IPF. This manuscript discusses the data described above and their implications regarding IPF pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504233     DOI: 10.2174/138161207780618885

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  58 in total

1.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

2.  Mediators leading to fibrosis - how to measure and control them in tissue engineering.

Authors:  Xd Mu; Ih Bellayr; Tj Walters; Y Li
Journal:  Oper Tech Orthop       Date:  2010-06-01

3.  Evaluation of Renin and Soluble (Pro)renin Receptor in Patients with IPF. A Comparison with Hypersensitivity Pneumonitis.

Authors:  Montes Eduardo; Buendía-Roldan Ivette; Díaz-Piña Gabriela; Moreno-Avila Veronica; Ruiz Victor
Journal:  Lung       Date:  2019-10-15       Impact factor: 2.584

4.  The unfolded protein response controls ER stress-induced apoptosis of lung epithelial cells through angiotensin generation.

Authors:  Hang Nguyen; Bruce D Uhal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-16       Impact factor: 5.464

5.  Angiotensin-converting enzyme (ACE) gene polymorphisms are associated with idiopathic pulmonary fibrosis.

Authors:  Soo-Taek Uh; Tae-Hoon Kim; Eun-Young Shim; An-Soo Jang; Sung-Woo Park; Jong-Sook Park; Byung-Lae Park; Byoung Whui Choi; Hyoung Doo Shin; Dong Soon Kim; Choon-Sik Park
Journal:  Lung       Date:  2013-05-09       Impact factor: 2.584

6.  Pin1 protein regulates Smad protein signaling and pulmonary fibrosis.

Authors:  Zhong-Jian Shen; Ruedi K Braun; Jie Hu; Qifa Xie; Haiyan Chu; Robert B Love; Levi A Stodola; Louis A Rosenthal; Renee J Szakaly; Ronald L Sorkness; James S Malter
Journal:  J Biol Chem       Date:  2012-05-21       Impact factor: 5.157

7.  JunD and HIF-1alpha mediate transcriptional activation of angiotensinogen by TGF-beta1 in human lung fibroblasts.

Authors:  Amal Abdul-Hafez; Ruijie Shu; Bruce D Uhal
Journal:  FASEB J       Date:  2009-02-11       Impact factor: 5.191

8.  Angiotensinogen promoter polymorphisms predict low diffusing capacity in U.S. and Spanish IPF cohorts.

Authors:  My-Trang T Dang; Chenyang Gu; Jeannie I Klavanian; Katherine A Jernigan; Karen H Friderici; Yuehua Cui; Maria Molina-Molina; Julio Ancochea; Antoni Xaubet; Bruce D Uhal
Journal:  Lung       Date:  2013-05-30       Impact factor: 2.584

9.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

Review 10.  Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.

Authors:  Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic
Journal:  Hypertension       Date:  2020-09-28       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.